


Chapter 9


Supplemental Data 5: Raw figures stratified by remission status

Generic quality of life in treated Cushing syndrome patients (no remission).



Higher score represents lower quality of life: SCL-90-R


Generic quality of life in treated Cushing syndrome patients (remission).




Higher score represents lower quality of life: EuroQoL-5D (all scales except VAS), GHQ-28, NHP, physical symptoms checklist, PSI (except well-being), SCL-90(-R), SF-20, SIP, SRT

Partially overlapping populations: Milian 2013 (2) and Milian 2014; Tiemensma 2011 and Van Aken 2005; Sonino 2006 and Sonino 2007


Generic quality of life in Cushing syndrome patients before versus after treatment (remission).



Generic quality of life in Cushing syndrome patients after treatment versus healthy controls (no remission).




Generic quality of life in Cushing syndrome patients after treatment versus healthy controls (remission).




Partially overlapping populations: Sonino 2006 and Sonino 2007

Disease specific quality of life in treated Cushing syndrome patients (no remission).




Disease specific quality of life in treated Cushing syndrome patients (remission).




Higher score represents lower quality of life: Tuebingen CD-25


Disease specific quality of life in Cushing syndrome patients before versus after treatment (no remission).



Disease specific quality of life in Cushing syndrome patients before versus after treatment (remission).




Quality of life: domain anxiety, in treated Cushing syndrome patients (remission).




Higher score represents lower quality of life: BAI, FQ, HADS, MASQ-30, STAI
 Partially overlapping populations: Andela 2013, Tiemensma 2010, and Van Aken 2005

Quality of life: domain anxiety, in Cushing syndrome patients after treatment versus healthy controls (remission).



Partially overlapping populations: Andela 2013, Tiemensma 2010, and Van Aken 2005


Quality of life: domain depression, in treated Cushing syndrome patients (remission).




Higher score represents lower quality of life: BDI(-II), HADS, HRSD, IDS, MADRS

Partially overlapping populations: Andela 2013, Tiemensma 2010, and Van Aken 2005

Quality of life: domain depression, in Cushing syndrome patients before versus after treatment (remission).




Quality of life: domain depression, in Cushing syndrome patients after treatment versus healthy controls (remission).




Partially overlapping populations: Andela 2013, Tiemensma 2010, and Van Aken 2005

Quality of life: domain fatigue, in treated Cushing syndrome patients (remission).




Higher score represents lower quality of life: CIS, MFI-20, MFS


Quality of life: domain fatigue, in Cushing syndrome patients after treatment versus healthy controls (remission).




Cognitive function: intelligence, in treated Cushing syndrome patients (remission).




Cognitive function: intelligence, in Cushing syndrome patients before versus after treatment (remission).



Cognitive function: intelligence, in Cushing syndrome patients after treatment versus healthy controls (remission).




Cognitive function: executive functioning, in treated Cushing syndrome patients (remission).




Higher score represents worse cognitive function: TMT


Cognitive function: executive functioning, in Cushing syndrome patients before versus after treatment (remission).




Cognitive function: executive functioning, in Cushing syndrome patients after treatment versus healthy controls (remission).




Cognitive function: attention, in treated Cushing syndrome patients (remission).




Cognitive function: attention, in Cushing syndrome patients before versus after treatment (remission).




Cognitive function: attention, in Cushing syndrome patients after treatment versus healthy controls (remission)




Quality of life: SF-36, in treated Cushing syndrome patients (no remission).




Quality of life: SF-36, in treated Cushing syndrome patients (remission).




Quality of life: SF-36, in Cushing syndrome patients after treatment versus healthy controls (no remission).



Quality of life: SF-36, in Cushing syndrome patients after treatment versus healthy controls (remission).




Quality of life: SCL-90-R, in treated Cushing syndrome patients (remission).




Higher score represents lower quality of life: SCL-90-R


Quality of life: SCL-90-R, in Cushing syndrome patients before versus after treatment (remission).




Quality of life: CushingQoL, in treated Cushing syndrome patients (no remission).




Quality of life: CushingQoL, in treated Cushing syndrome patients (remission).




Quality of life: CushingQoL, in Cushing syndrome patients before versus after treatment (no remission).



Quality of life: CushingQoL, in Cushing syndrome patients before versus after treatment (remission).




Quality of life: HADS, in treated Cushing syndrome patients (remission).




Higher score represents lower quality of life: HADS

Cognitive function: DSST, in treated Cushing syndrome patients (remission).



Cognitive function: DSST, in Cushing syndrome patients before versus after treatment (remission).



Cognitive function: DSST, in Cushing syndrome patients after treatment versus healthy controls (remission).

